1、Zhiwei Chen*, Xiaomin Niu, Ziming Li, Yongfeng Yu, Xiangyun Ye, Shun Lu, Zhen Chen. Effect of ubiquitin carboxy-terminal hydrolase 37 on apoptotic in A549 cells. Cell Biochem Funct,2011;29(2):142-8
2、Zhiwei Chen*, Ziming Li, Xiaomin Niu, Xiangyun Ye, Yongfeng Yu, Shun Lu, Zhen Chen. The effect of CYP1A1 polymorphisms on the risk of lung cancer a global meta-analysis based on 71 case–control studies.. Mutagenesis,2011;26(3):437-46
3、Zhengbo Song, Yongfeng Yu, Zhiwei Chen*, Shun Lu. Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients.. Med Oncol,2011;28 Suppl 1:S605-12
4、Xiaomin Niu,Zhiwei Chen*,Shengping Shen, Yun Liu, Daizhan Zhou, Jie Zhang, Ziming Li,Yongfeng Yu,Meilin Liao, Shun Lu, Lin He. Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population.. J Thorac Oncol.,2010;5(5):658-66
5、Zhiwei Chen*, Yongfeng Yu, Da Fu, Ziming Li, Xiaoming Niu, Meilin Liao 1, Shun Lu. Functional roles of PC-PLC and Cdc20 in the cell cycle, proliferation, and apoptosis.. Cell Biochem Funct,2010;28(4):249-57
6、Yong-feng Yu, Zhi-wei Chen*, Zhen Zhou, Zheng-bo Song, Zi-ming Li, Hong Jian, Yi-fei Zhang, Shun Lu. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China. . Chemotherapy.,2010;56(6):472-477
|
